Please login to the form below

Not currently logged in
Email:
Password:

Superior efficacy-dose ratio for Lantus

A 76 per cent higher dose of insulin detemir is needed to achieve similar, well-tolerated glycaemic control when compared to Lantus

A study has shown that a 76 per cent higher dose of insulin detemir is needed to achieve similar, well-tolerated glycaemic control when compared to Lantus.

Sanofi-aventis (S-A) announced the results during the 45th annual meeting of the European Association for the Study of Diabetes in Vienna.

In the head-to-head, randomised, non-inferiority controlled clinical trial of 964 patients, those taking Lantus required an average daily dose of 43.5 units to achieve the primary endpoint of HbA1c below 7 per cent without symptomatic hypoglycaemia, compared to patients on insulin detemir, who received 76.5 units – an increase of 76 per cent. Despite lower doses of insulin in the glargine group, Lantus once-daily and insulin detemir twice-daily resulted in similar improvements in glycaemic control and a similar risk of hypoglycaemia. Patients in the Lantus arm of the study also achieved significantly lower fasting blood glucose (-63.1 mg/dL Lantus vs -57.7 mg/dL).

"This study demonstrated that for insulin-naïve patients with type 2 diabetes, initiating insulin therapy with once-daily glargine achieved the same glycaemic control as twice-daily detemir, with somewhat more weight gain, but lower insulin doses," stated study investigator, Hertzel Gerstein, professor of diabetes medicine, faculty of health sciences, Hamilton, Canada.

Patients taking Lantus once-daily reported a significantly greater treatment satisfaction over insulin detemir twice-daily, with over 50 per cent less drop-outs (4.6 per cent vs 10.1 per cent). Discontinuations in patients taking insulin detemir were primarily due to adverse events, including skin reactions.

The insulin-naïve patients were aged between 40 and 75 and had had type 2 diabetes for at least one year with sub-optimal blood glucose control using glucose-lowering drugs.

There was limited weight gain in both groups, with patients on insulin detemir experiencing less weight gain (0.6 versus 1.4kg).

30th September 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics